A biotechnology company “Hepatera” organized phase Ib-IIa clinical study of Myrcludex B in specialized clinical centers in Moscow, St. Petersburg, Chelyabinsk and Samara.
According to the PR office of the company, the developed drug is a synthesized peptide chain, similar in structure to a membrane protein of hepatitis B. Due to this structure it competitively binds to receptors on liver cells and blocks the virus. “Thus, the drug candidate provides for the recovery of the liver tissue and prevents further progression of the disease and the development of complications such as cirrhosis and hepatocellular carcinoma”.
“The Company intends to confirm the effectiveness of the drug against HBsAg clearance and its effect on the viral load, as well as demonstrate good tolerability and safety of the drug in the target population of patient”.
It is expected that the results of the study, which was launched in Russia in the largest specialized centers, will be available by the end of 2013.